Trial Profile

Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gadolinium chelated polysiloxane based nanoparticle (Primary)
Indications Adenocarcinoma; Non-small cell lung cancer; Pancreatic ductal carcinoma
Focus Adverse reactions
Acronyms Nano-SMART

14 May 2026 Planned End Date changed from 10 Sep 2028 to 10 Apr 2030.
06 May 2026 Planned End Date changed from 10 Sep 2027 to 10 Sep 2028.
06 May 2026 Planned primary completion date changed from 10 Apr 2026 to 10 Apr 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com